Caris Life Sciences Inc.
CAI | NASDAQ
$32.27
-$2.06 (-6.00%)
Nov 2, 2026, 3:16 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|
Revenue | 812.03M | 412.26M | 306.13M | 258.49M | 294.01M |
Cost of Revenue | 272.87M | 233.48M | 216.82M | 178.46M | 109.86M |
Gross Profit | 539.17M | 178.78M | 89.31M | 80.02M | 184.16M |
Operating Income | 45.11M | -257.12M | -319.55M | -315.76M | 139.09M |
Interest Income | 16.5M | 7.12M | 11.26M | 947K | n/a |
Pretax Income | -68.09M | -281.89M | -341.42M | -320.83M | 29.53M |
Net Income | -537.96M | -281.89M | -341.42M | -320.83M | 27.73M |
Selling & General & Admin | 392.47M | 321.86M | 291.48M | 294.51M | 27.31M |
Research & Development | 45.31M | 113.92M | 116.88M | 101.27M | n/a |
Other Expenses | 56.27M | 128K | 500K | n/a | 17.76M |
Operating Expenses | 494.06M | 435.9M | 408.86M | 395.78M | 45.07M |
Interest Expense | 56.85M | 50.03M | 31.61M | 26.68M | 61.57M |
Selling & Marketing Expenses | 167.51M | 148.3M | 139.53M | 138.36M | n/a |
Cost & Expenses | 766.92M | 669.38M | 625.68M | 574.24M | 154.93M |
Income Tax Expense | 469.87M | n/a | n/a | n/a | 1.8M |
Shares Outstanding (Basic) | 282.33M | 254.66M | 254.66M | 254.79M | 17.95M |
Shares Outstanding (Diluted) | 289.89M | 254.66M | 254.66M | 254.79M | 17.95M |
EPS (Basic) | -1.91 | -2.70 | -1.82 | -1.57 | 1.55 |
EPS (Diluted) | -1.86 | -2.70 | -1.82 | -1.57 | 1.55 |
EBITDA | 11.38M | -182.95M | -260.8M | -245.89M | 254.46M |
EBIT | -11.24M | -231.87M | -309.81M | -294.15M | 143.81M |
Depreciation & Amortization | 22.62M | 48.91M | 49M | 48.25M | 110.65M |
Add to Watchlist
Select watchlists to add or remove CAI